Purdue Pharma asserts patent infringement claims under Hatch-Waxman Act related to OxyContin® against Mylan
Clients Purdue Pharma L.P.
Jones Day successfully represented Purdue Pharma L.P. in a Hatch-Waxman patent infringement action against defendants, relating to the defendants' submission of an Abbreviated New Drug Application to the FDA seeking approval of generic versions of OxyContin®, a widely prescribed treatment for pain relief. Purdue came to a successful resolution of the dispute through settlement.
Purdue Pharma et al. v. Mylan Pharmaceuticals Inc., et al., Case No. 1:15-cv-01155-SLR (D. Del.)